Shares of Axsome Therapeutics (NASDAQ: AXSM) were sinking 7.5% as of 11:24 a.m. ET on Monday. And while many stocks were tumbling due to the Bank of Japan's interest rate hike, that wasn't the main cause of Axsome's decline. Instead, the biopharmaceutical company announced disappointing second-quarter results before the market opened today.
Axsome reported net product revenue in the second quarter of $87.2 million, up 87% year over year. This result topped the consensus Wall Street revenue estimate of $86.9 million. But the company posted a net loss in the quarter of $79.3 million, or $1.67 per share. Analysts surveyed by LSEG were expecting a loss of $1.33 per share.
Why was Axsome's second-quarter loss so much worse than expected?
Research and development costs more than doubled year over year to nearly $49.9 million. Its selling, general, and administrative costs jumped 31% to $103.6 million.
The company noted in its press release announcing the second-quarter results that the net loss reflected $26 million in noncash charges. Much of this amount stemmed from noncash stock-based compensation.
Is Axsome stock a buy on the dip?
Risk-averse investors will probably prefer to stay on the sidelines. However, I think Axsome's sell-off could present a great buying opportunity for aggressive investors. The company has several catalysts on the way that could send shares flying higher, including a potential U.S. regulatory approval for AXS-07 in treating migraine.
Should you invest $1,000 in Axsome Therapeutics right now?
Before you buy stock in Axsome Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Axsome Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $657,306!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of July 29, 2024
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axsome Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
